BIOMARKER:

EGFR wild-type

News alerts, weekly reports and conference planners

Entrez ID:

1956

Related biomarkers:

‹

›

EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks (New C3) atezolizumab Sensitive : C3 Nat Med - 2wk	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks atezolizumab Sensitive : C3 Nat Med - 2 weeks - (New C3)
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks (New B) atezolizumab Sensitive : B Cancer Med - 3wk	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks atezolizumab Sensitive : B Cancer Med - 3 weeks - (New B)
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) anlotinib Sensitive : C2 ESMO 2022 - 3wk	anlotinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks anlotinib Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	docetaxel + BPI 2358 Sensitive: B - Late Trials docetaxel + BPI 2358 Sensitive : B	docetaxel + BPI 2358 Sensitive: B - Late Trials docetaxel + BPI 2358 Sensitive : B
EGFR wild-type	Lung Non-Small Cell Squamous Cancer	EGFR wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab Sensitive: B - Late Trials cemiplimab Sensitive : B	cemiplimab Sensitive: B - Late Trials cemiplimab Sensitive : B
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab Sensitive: B - Late Trials cemiplimab Sensitive : B	cemiplimab Sensitive: B - Late Trials cemiplimab Sensitive : B
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	toripalimab Sensitive: C2 – Inclusion Criteria toripalimab Sensitive : C2	toripalimab Sensitive: C2 – Inclusion Criteria toripalimab Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	erlotinib + cabozantinib tablet Sensitive: C3 – Early Trials erlotinib + cabozantinib tablet Sensitive : C3	erlotinib + cabozantinib tablet Sensitive: C3 – Early Trials erlotinib + cabozantinib tablet Sensitive : C3
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	tislelizumab Sensitive: C3 – Early Trials tislelizumab Sensitive : C3	tislelizumab Sensitive: C3 – Early Trials tislelizumab Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	AK112 Sensitive: C3 – Early Trials AK112 Sensitive : C3	AK112 Sensitive: C3 – Early Trials AK112 Sensitive : C3
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	AZD8330 Sensitive: D – Preclinical AZD8330 Sensitive : D	AZD8330 Sensitive: D – Preclinical AZD8330 Sensitive : D
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	PF-04691502 Sensitive: D – Preclinical PF-04691502 Sensitive : D	PF-04691502 Sensitive: D – Preclinical PF-04691502 Sensitive : D
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D	GSK2126458 Sensitive: D – Preclinical GSK2126458 Sensitive : D
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	gefitinib Sensitive: D – Preclinical gefitinib Sensitive : D	gefitinib Sensitive: D – Preclinical gefitinib Sensitive : D

EGFR wild-type

Associations